Psychiatric disorders and psychotropic medication use in elderly persons with diabetes

Annals of Long-Term Care

Volumn 14, Issue 7, 2006, Pages 39-47

  Feil, Denise ^a,b,c   Weinreb, Jane ^b,c,d   Sultzer, David ^c,e  

^a Veterans Affairs Health Services Research and Development Service (#RCD 02 028)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Diabetes Program

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GALANTAMINE; INSULIN; MEMANTINE; MIRTAZAPINE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AGITATION; ALCOHOL ABUSE; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; CAREGIVER SUPPORT; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DEPRESSION; DIET RESTRICTION; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ELDERLY CARE; ENDOCRINE DISEASE; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE MANAGEMENT; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PREVALENCE; PSYCHOSIS; PSYCHOTHERAPY; QT PROLONGATION; REVIEW; RISK FACTOR; SEDATION; SELF CARE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33746901105     PISSN: 15247929     EISSN: 15247929     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Diabetes: Disabling, deadly, and on the rise. Centers for Disease Control and Prevention. Department of Health and Human Services. Available at: http://www.cdc.gov/nccdphp/aag/aag_ddt.htm. Accessed March 16, 2006.
2. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490:169-175.
3. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease, and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002;14:77-83.
4. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999;52:971-975.
5. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937-1942.
6. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262.
7. Elias PK, Elias MF, D'Agostino RB, et al. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997;20:1388-1395.
8. Bayer AJ, Johnston J, Sinclair AJ. Impact of dementia on diabetic care in the aged. J R Soc Med 1994; 87:619-621.
9. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: Impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract 2000;50:203-213.
10. Feil D, Marmon T, Unutzer J. Cognitive impairment, chronic medical illness, and risk of mortality in an elderly cohort. Am J Geriatr Psychiatry 2003;11:551-560.
11. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230-2235.
12. Messier C. Diabetes, Alzheimer's disease, and apolipoprotein genotype. Exp Gerontol 2003;38:941-946.
13. Yaffe K, Blackwell, T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-663.
14. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment, and dementia. Diabet Med 1999;16:93-112.
15. Abbatecola AM, Paolisso G, Lamponi M, et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatrics Soc 2004;52:1713-1718.
16. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function J Clin Exp Neuropsychol 2004;26(8):1044-1080.
17. Frier BM. Hypoglycaemia and cognitive function in diabetes. Int J Clin Pract Suppl 2001;(123):30-37.
18. Draelos MT, Jacobson AM, Weinger K, et al. Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemia. Am J Med 1995;98:135-144.
19. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002;(4):CD003804.
20. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351(1):56-67.
21. Mills EJ, Chow TW. Randomized controlled trials in long-term care residents with dementia: A systematic review. J Am Med Dir Assoc 2003;4(6):302-307.
22. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004(Suppl 1);24:7-14.
23. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118 (Suppl 2):15S-22S.
24. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005 293:596-608.
25. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/cder/ drug/advisory/antipsychotics.htm. Accessed March 16, 2006.
26. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.
27. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care 2001;24:1069-1078.
28. Lyness JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med 1999;14:249-254.
29. Nichols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 2003;26:744-749.
30. Musselman D, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biol Psychiatry 2003;54:317-329.
31. Eaton WW, Armenian H, Gallo J, et al. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996;22:1097-1102.
32. Kawakami N, Takatsuka N, Shimiza H, Ishibashi H. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999;22:1071-1076.
33. Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004;27:2856-2862.
34. Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of Type 2 diabetes and depressive symptoms in the elderly: The Rancho Bernardo Study. Diabet Med 2004;21:1185-1191.
35. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: A meta-analysis. Psychosom Med 2001;63:619-630.
36. Viinamaki H, Niskanen L, Uusitupa M. Mental well-being in people with noninsulin-dependent diabetes. Acta Psychiatr Scand 1995;92(5):392-397.
37. Lustman PJ, Clouse RE. Depression in diabetic patients: The relationship between mood and glycemic control. J Diabetes Complications 2005;19:113-122.
38. Egede LE. Diabetes, major depression, and functional disability among U.S. adults. Diabetes Care 2004;27:421-428.
39. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27:2154-2160.
40. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: A meta-analytic review of the literature. Diabetes Care 2000;23:934-942.
41. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25:464-470.
42. Arroyo C, Hu FB, Ryan LM, et al. Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care 2004;27:129-133.
43. Surwit RS, Schneider MS, Feinglos MN. Stress and diabetes mellitus. Diabetes Care 1992;15:1413-1422.
44. Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: What is the relationship? J Affective Disord 2004;79:81-95.
45. Feil D, Kumar A. The neuropsychiatry of subcortical ischemic brain disease. Curr Psychiatry Rep 1999;1:69-77.
46. de Groot JC, de Leeuw F, Oudkerk M, et al. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071-1076.
47. Centers for Disease Control and Prevention (CDC).Serious psychological distress among persons with diabetes - New York City, 2003. MMWR Morb Mortal Wkly Rep 2004;53:1089-92.
48. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care. 2000;23:1556-62.
49. Rubin RR, Ciechanowski P, Egede LE, et al. Recognizing and treating depression in patients with diabetes. Curr Diabetes Rep 2004;4:119-125.
50. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: A randomized double-blind placebo-controlled trial. Diabetes Care 2000;23:618-623.
51. Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;129:613-621.
52. Williams JW Jr, Katon W, Lin EH, et al; IMPACT Investigators. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 2004;140:1015-1024.
53. Alexopoulos GS, Katz IR, Reynolds CF 3rd, et al. Pharmacotherapy of depression in older patients: A summary of the expert consensus guidelines. J Psychiatr Pract 2001;7:361-376.
54. Goodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997;33:261-264.
55. Finkel SI, Richter EM, Clary CM, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry 1999;7:221-227.
56. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004;164:1395-1404.
57. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21:1659-1668.
58. Heiser P, Singh S, Krieg JC, Vedder H. Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res 2005 [Epub ahead of print.].
59. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123-1130.
60. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999;21:454-463.
61. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry 1995; 28:35-44.
62. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: A review. Obes Rev 2004;5:115-121.
63. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: A systematic review. Ann Intern Med 2004;140:211-219.
64. Van de Wiel A. Diabetes mellitus and alcohol. Diabetes Metab Res Rev 2004;20:263-267.
65. Emanuele NV, Swade TF, Emanuele MA. Consequences of alcohol use in diabetics. Alcohol Health Res World 1998;22:211-219.
66. Shai I, Rimm EB, Schulze MB, et al. Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia 2004;47:1760-1767.
67. Fleming M, Brown R, Brown D. The efficacy of a brief alcohol intervention combined with percent CDT feedback in patients being treated for type 2 diabetes and/or hypertension. J Stud Alcohol 2004;65:631-637.
68. Reiff-Hekking S, Ockene JK, Hurley TG, Reed GW. Brief physician and nurse practitioner-delivered counseling for high-risk drinking. Results at 12-month follow-up. J Gen Intern Med 2005;20:7-13.
69. Saitz R, Horton NJ, Sullivan LM, et al.Addressing alcohol problems in primary care: A cluster randomized, controlled trial of a systems intervention. The screening and intervention in primary care (SIP) study. Ann Intern Med 2003;138:372-382.
70. Fleming MF, Mundt MP, French MT, et al. Brief physician advice for problem drinkers: Long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res 2002;26:36-43.
71. Mundt MP, French MT, Roebuck MC, et al. Brief physician advice for problem drinking among older adults: An economic analysis of costs and benefits. J Stud Alcohol 2005;66(3):389-394.
72. Boulton AJM, Vinik AI, Arezzo JC, et al; American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005;28:956-962.
73. Krause S, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003;19:306-314.
74. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280:1831-1836.
75. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005;116(1-2):109-118.
76. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27:1458-1486.
77. Lesser H. Sharma U. LaMoreaux L. Poole RM Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63(11):2104-10, 2004 Dec 14
78. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;110:697-706. [Erratum in: Pain 2005;113(1-2):248.
79. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain relief in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
80. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003;64(Suppl 8):22-29.
81. Boulton AJM. Management of diabetic peripheral neuropathy. Clinical Diabetes 2005;23:9-15.
82. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-144.
83. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-552.
84. Mulsant BH, Pollock BG. Psychopharmacology. In: Blazer DG, Steffens DC, Busse EW, eds. The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 3rd ed. Washington, D.C.: American Psychiatric Publishing, Inc.; 2004:387-411.
85. Lee PE,Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: Systematic review. Brit Med J 2004;329:75.
86. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for using antipsychotic drugs in older patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 (Suppl 2):5-104.
87. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202.
88. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57:1583-1588.